On September 29, GeLongHui reported that pacific shuanglin bio-pharmacy (000403.SZ) conducted an investor survey on September 26, 2024, regarding whether the growth in demand for ribavirin is a short-term market behavior or long-term demand growth. The company stated that in recent years, society's awareness of blood products has significantly increased, especially the market awareness of ribavirin has improved markedly. Currently, the domestic market faces a shortage of ribavirin supply due to high demand, and overseas demand has also increased significantly. Considering the market share and indications of ribavirin abroad, there is huge potential for future growth in the ribavirin market, indicating that the growth in demand for ribavirin belongs to long-term demand growth.
派林生物(000403.SZ)：目前国内市场静丙销售供不应求，海外市场需求也明显增加
Pacific Shuanglin Bio-Pharmacy (000403.SZ): Currently, domestic market's sales of ribavirin are in short supply, and overseas market demand is also significantly increasing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated